Shots:
- The P-III CheckMate -9ER trial involves assessing Opdivo + Cabometyx vs sunitinib in 651 patients with previously untreated advanced or metastatic RCC
- Results: @median follow-up of two years (23.5 mos.); median PFS (17.0 vs 8.3mos.), ORR (54.8% vs. 28.4%); Disease control rate (88.2% vs. 69.9%); CR (9.3% vs 4.3%); OS (34% reduction in risk of death). In an exploratory subgroup analysis of 75 patients with sarcomatoid features, 64% reduction in risk of death, PFS (10.3 vs 4.2mos.); ORR (55.9% vs 22.0%)
- The findings showing ongoing efficacy benefits and patient-reported outcomes will be presented at the 2021 Genitourinary Cancers Symposium
Click here to read full press release/ article | Ref: BMS | Image: BMS
The post BMS Report Results of Opdivo (nivolumab) + Cabometyx (cabozantinib) in P-III CheckMate -9ER Trial for 1L Treatment of Advanced Renal Cell Carcinoma first appeared on PharmaShots.
